Secukinumab,
does it really help with Skin clearance and itch improvement in moderate-to-severe plaque psoriasis?
research showsSecukinumab is rated B because it markedly improves lesions and itch in moderate-to-severe plaque psoriasis. Week-12 PASI 75 rates with 300 mg were 81.6% and 77.1% in ERASURE and FIXTURE, versus 4.5% and 4.9% with placebo; FIXTURE also exceeded 44.0% with etanercept. Clearance and symptom relief are direct treatment goals, but not hard outcomes such as mortality or major complications, and long-term immune safety requires monitoring, yielding 76 points.
ads claimComplete cure or one-and-done treatment exceeds the evidence. Many, but not all, patients reach clear or almost-clear skin, and maintenance dosing plus infection surveillance remain necessary.
Useful facts when choosing a product
- Cosentyx is a prescription biologic for patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- A common adult subcutaneous regimen uses weekly loading doses followed by maintenance every four weeks; the individual prescription and label control dosing.
- Tuberculosis evaluation and vaccination review are required before therapy, and serious infection during treatment requires clinical assessment.
- Upper respiratory and Candida infections can occur, inflammatory bowel disease may develop or worsen, and live vaccines should be avoided.
What the research actually shows
Langley and colleagues randomized 2,044 patients with moderate-to-severe plaque psoriasis in ERASURE and FIXTURE to secukinumab 300 mg or 150 mg, placebo, and etanercept in FIXTURE. Week-12 PASI 75 rates with 300 mg were 81.6% and 77.1%, compared with 4.5% and 4.9% with placebo and 44.0% with etanercept. IGA 0/1, patient-reported itch, pain, scaling, and DLQI also improved, with most responses sustained through week 52 during continued treatment. CLEAR further supported greater clearance than ustekinumab.
Why this is classified as B (76)
Two large phase 3 trials consistently improved PASI 75, IGA, and patient-reported symptoms and showed superiority to active-control etanercept. Clearance and itch are direct treatment goals rather than hard outcomes, giving B with 76 points.
Counterpoint. Disease distribution, joint symptoms, previous biologics, infection or bowel-disease history, and patient preferences may favor another biologic.
Rejudgment record. New verdict — Applied B for replicated large randomized improvements in PASI 75, IGA 0/1, and patient-reported symptoms in ERASURE and FIXTURE, including superiority to etanercept on direct psoriasis treatment goals
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| PASI 75 improvement in skin lesions | B | Responses were markedly higher than placebo in two large phase 3 trials and also exceeded etanercept. |
| Achievement of clear or almost-clear skin | B | Modified IGA 0/1 and active-comparator PASI 90 results support skin clearance. |
| Improvement in itch and skin-related quality of life | B | Patient-reported itch, pain, scaling, and DLQI improved, although maintenance therapy is required. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| ERASURE and FIXTURE (Langley RG et al.). 2014 | Two phase 3 multicenter randomized double-blind placebo- and active-controlled trials | 2,044 | Novartis Pharma | Week-12 PASI 75 and modified IGA 0/1; symptoms and DLQI | PASI 75 with 300 mg was 81.6% and 77.1%, versus 4.5% and 4.9% with placebo and 44.0% with etanercept in FIXTURE. | Pivotal large randomized evidence on direct treatment goals |
| CLEAR (Thaçi D et al.). 2015 | Phase 3 randomized double-blind ustekinumab-controlled superiority trial | 676 | Novartis Pharma | Week-16 PASI 90 skin clearance | Secukinumab produced a higher PASI 90 response than ustekinumab. | Active-comparator replication |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Secukinumab x skin clearance and itch improvement in moderate-to-severe plaque psoriasis — Evidence Grade B·76. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/secukinumab-plaque-psoriasis-clearance-itch/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.